We recently compiled a list of the Jim Cramer Recently Talked About These 11 S&P 500 Stocks. In this article, we are going to ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

The latest to join the ranks is the so-called “natural Mounjaro” drink for weight loss. Recipes vary slightly depending on which one you find, but the natural Mounjaro drink generally consists of ...

FTC Chair Lina Khan has the big three pharmacy benefit managers in sight—UnitedHealth's OptumRx, Cigna's Express Scripts and CVS Caremark Rx. © 2024 Fortune Media ...

The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for ...

The company attributed the revision to lower-than-expected sales of tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. “It’s always disappointing to miss your own ...

Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make ...

Pharmacy benefit managers CVS Caremark, OptumRx and Express Scripts inflated costs for specialty generic drugs to treat diseases such as cancer and HIV to the tune of $7.3 billion over six years ...

One jab that's been capturing public attention and headlines lately is Mounjaro. The Labour Party unveiled plans to introduce the weight-loss jab Mounjaro on the NHS in England in December ...

The report accuses CVS’ Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx of jacking up the price of lifesaving drugs by hundreds and thousands of percent. The so-called “Big ...

The world of weight loss medicine is experiencing a dramatic transformation and you’re about to learn why. A groundbreaking study published in one of the most prestigious medical journals has ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the ...